Abstract:Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background Cisplatin (DDP) is a widely used anticancer drug but its application is limited by side effects. We have previously shown that selective delivery of DDP to tumors using novel nanoparticles could significantly enhance antitumor effects with reduced toxicity. Since our group has shown that 45% of 105 HNSCC primary tumors are positive for folate receptor (FR) in Head Neck 31:475-81, 2009, we further developed DDP-loaded folate-targeted iron oxide nanoparticles (FA-IO-DDP) for HNSCC imaging and therapy. Methods HNSCC cell lines were screened for FR expression by Western blot analysis and its surface expression was confirmed by FACS. Intracellular platinum (Pt) and Pt-DNA adducts were quantified by ICP-mass spectrometry. MRI was used to detect T2 signal changes induced by iron oxide. Near infrared dye (Cy-5.5) conjugated nanoparticles were used to assess accumulation of the nanoparticles in the tumor tissues and cells. Efficacy and toxicity were assessed using nude mice bearing FR expressing SQCCY1 xenograft using 1mg/kg of free DDP and IO-DDP and FA-IO-DDP equivalent to 0.3mg/kg of free DDP. Results Five HNSCC cell lines expressing surface FR were identified among 16 HNSCC cell lines screened. Intracellular Pt and Pt-DNA adducts were increased in FR-positive PCI15B cells treated with FA-IO-DDP by 1.6-fold and 3.8-fold, respectively, compared to cells treated with non-targeted IO-DDP and free DDP (p<0.05). A similar degree of enhanced uptake was observed in FR-expressing SQCCY1 cells but not in FR-negative Tu212 cells. In a subcutaneous SQCCY1 xenograft model in nude mice, tumor targeted FA-IO-DDP showed significantly enhanced efficacy compared to free DDP (p<0.05). Nanoparticles had better efficacy compared to free drug even at lower concentration. The average tumor volume in the FA-IO-DDP treated group was 243.0±412.4 mm3 compared to 541.4±744.5 mm3 and 3324.6±501.3 mm3 in the IO-DDP and free DDP groups, respectively. A notable change in T2 signal in MRI and infrared signal in optical imaging was detected in nude mice bearing SQCCY1 cells 24 hours after treatment with FA-IO-DDP. Conclusion Our study showed that novel FR-IO-DDP nanoparticles remarkably enhanced the antitumor effects of DDP in vivo in nude mice bearing FR-positive HNSCC cells and can accumulate in FR-expressing tumors in vivo as detected by MRI and near infrared imaging. Results from the in vitro studies suggest that the effect is mediated by increased intracellular Pt concentration and Pt-DNA adducts. Further analyses in tissues from xenograft mice are ongoing. This work was supported by Chester Rochfort Endowment Fund/Winship Cancer Institute of Emory University and NIH U01CA151802-02, 1R01CA154846-01 and 1U01CA151810-02. Citation Format: Hyunseok Kang, Jing Huang, Xianghong Peng, Zhuo (Georgia) Chen, Hui Mao, Dong M. Shin. Folate receptor targeted iron oxide nanoparticles loaded with cisplatin for imaging and therapy in head and neck squamous cell carcinoma (HNSCC). [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4528. doi:10.1158/1538-7445.AM2013-4528

The Antitumor Effect of Folic Acid Conjugated-Auricularia Auricular Polysaccharide-Cisplatin Complex on Cervical Carcinoma Cells in Nude Mice.

Auricularia Auriculajudae Polysaccharide-Cisplatin Complexes Conjugated with Folic Acid As New Tumor Targeting Agents.

Anti-tumor Efficacy of Polymer–platinum(ii) Complex Micelles Fabricated from Folate Conjugated PEG-graft-α,β-poly [(N-Amino Acidyl)-Aspartamide] and Cis-Dichlorodiammine Platinum(ii) in Tumor-Bearing Mice

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

Preliminary Study on Pharmacokinetics and Antitumor Pharmacodynamics of Folic Acid Modified Crebanine Polyethyleneglycol-Polylactic Acid Hydroxyacetic Acid Copolymer Nanoparticles

A Study of the Synergistic Effect of Folate-Decorated Polymeric Micelles Incorporating Hydroxycamptothecin with Radiotherapy on Xenografted Human Cervical Carcinoma

Preparation of Chitosan-Polyaspartic Acid-5-fluorouracil Nanoparticles and Its Anti-Carcinoma Effect on Tumor Growth in Nude Mice.

Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer

A novel targeted anticancer drug delivery strategy: Cnidium officinale polysaccharide conjugated with carboxymethyl-5-fluorouracil and folic acid for ovarian cancer therapy

Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma

Folate-targeted Iron Oxide Nanoparticles Loaded with Cisplatin for Imaging and Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC).

Antitumor Activity of a Novel Double-Targeted System for Folate Receptor-Mediated Delivery of Mitomycin C

Abstract 4528: Folate receptor targeted iron oxide nanoparticles loaded with cisplatin for imaging and therapy in head and neck squamous cell carcinoma (HNSCC).

Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, Β-Cyclodextrin-based Drug Complexes for Cancer Treatment.

In Vitro and in Vivo Antitumor Study of Folic Acid-Conjugated Carboxymethyl Chitosan and Phenylboronic Acid–based Nanoparticles

Folate-modified Annonaceous acetogenins nanosuspensions and their improved antitumor efficacy.

Combination of ovalbumin-coated iron oxide nanoparticles and poly(amidoamine) dendrimer-cisplatin nanocomplex for enhanced anticancer efficacy

Preparation of FA-targeted magnetic nanocomposites co-loading TFPI-2 plasmid and cis-platinum and its targeted therapy effects on nasopharyngeal carcinoma

Antitumor Activity Of Folate-Targeted, Paclitaxel-Loaded Polymeric Micelles On A Human Esophageal Ec9706 Cancer Cell Line

Folate-conjugated beta-cyclodextrin-based polymeric micelles with enhanced doxorubicin antitumor efficacy.

Disulfiram/Copper Induces Antitumor Activity against Both Nasopharyngeal Cancer Cells and Cancer-Associated Fibroblasts through ROS/MAPK and Ferroptosis Pathways